Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 60067-1-Ig - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#60067-1-Ig, RRID:AB_2150840
- Product name
- Neuropilin 1 antibody
- Antibody type
- Monoclonal
- Description
- Neuropilin 1 antibody (Cat. #60067-1-Ig) is a mouse monoclonal antibody that shows reactivity with human, pig and has been validated for the following applications: FC, IF, WB,ELISA.
- Reactivity
- Human, Porcine
- Host
- Mouse
- Conjugate
- Unconjugated
- Isotype
- IgG
- Antibody clone number
- 2H3F6
- Vial size
- 20ul, 150ul
Submitted references CMTM6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1.
Cdc42 subcellular relocation in response to VEGF/NRP1 engagement is associated with the poor prognosis of colorectal cancer.
Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma.
Receptor-specific interactome as a hub for rapid cue-induced selective translation in axons.
RNA binding protein PUM2 promotes the stemness of breast cancer cells via competitively binding to neuropilin-1 (NRP-1) mRNA with miR-376a.
NRP1 haploinsufficiency predisposes to the development of Tetralogy of Fallot.
Dual Receptor Targeting Cell Penetrating Peptide Modified Liposome for Glioma and Breast Cancer Postoperative Recurrence Therapy.
Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss.
MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1.
Zheng Y, Wang C, Song A, Jiang F, Zhou J, Li G, Zhang W, Ye J, Ding X, Zhang W, Du Y, Zhang H, Wu H, Song X, Wu Y
American journal of cancer research 2020;10(6):1691-1709
American journal of cancer research 2020;10(6):1691-1709
Cdc42 subcellular relocation in response to VEGF/NRP1 engagement is associated with the poor prognosis of colorectal cancer.
Ma LL, Guo LL, Luo Y, Liu GL, Lei Y, Jing FY, Zhang YL, Tong GH, Jing ZL, Shen L, Tang MS, Ding YQ, Deng YJ
Cell death & disease 2020 Mar 5;11(3):171
Cell death & disease 2020 Mar 5;11(3):171
Perivascular Neuropilin-1 expression is an independent marker of improved survival in renal cell carcinoma.
Morin E, Lindskog C, Johansson M, Egevad L, Sandström P, Harmenberg U, Claesson-Welsh L, Sjöberg E
The Journal of pathology 2020 Apr;250(4):387-396
The Journal of pathology 2020 Apr;250(4):387-396
Receptor-specific interactome as a hub for rapid cue-induced selective translation in axons.
Koppers M, Cagnetta R, Shigeoka T, Wunderlich LC, Vallejo-Ramirez P, Qiaojin Lin J, Zhao S, Jakobs MA, Dwivedy A, Minett MS, Bellon A, Kaminski CF, Harris WA, Flanagan JG, Holt CE
eLife 2019 Nov 20;8
eLife 2019 Nov 20;8
RNA binding protein PUM2 promotes the stemness of breast cancer cells via competitively binding to neuropilin-1 (NRP-1) mRNA with miR-376a.
Zhang L, Chen Y, Li C, Liu J, Ren H, Li L, Zheng X, Wang H, Han Z
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019 Jun;114:108772
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2019 Jun;114:108772
NRP1 haploinsufficiency predisposes to the development of Tetralogy of Fallot.
Duran I, Tenney J, Warren CM, Sarukhanov A, Csukasi F, Skalansky M, Iruela-Arispe ML, Krakow D
American journal of medical genetics. Part A 2018 Mar;176(3):649-656
American journal of medical genetics. Part A 2018 Mar;176(3):649-656
Dual Receptor Targeting Cell Penetrating Peptide Modified Liposome for Glioma and Breast Cancer Postoperative Recurrence Therapy.
Qiu Y, Yu Q, Liu Y, Tang J, Wang X, Lu Z, Xu Z, He Q
Pharmaceutical research 2018 Apr 26;35(7):130
Pharmaceutical research 2018 Apr 26;35(7):130
Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss.
Saad S, Dharmapatni AASSK, Crotti TN, Cantley MD, Algate K, Findlay DM, Atkins GJ, Haynes DR
Acta biomaterialia 2016 Jan;30:311-318
Acta biomaterialia 2016 Jan;30:311-318
MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1.
Liu C, Wang Z, Wang Y, Gu W
Molecular and cellular biochemistry 2015 Jan;398(1-2):115-22
Molecular and cellular biochemistry 2015 Jan;398(1-2):115-22
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- human blood tissue were subjected to SDS PAGE followed by western blot with 60067-1-Ig(NRP1 antibody) at dilution of 1:500
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Confocal immunofluorescent analysis of human embronic stem cells with 60067-1-Ig at dilution of 1:100. DAPI was used to stain the cell nuclei (blue) at a concentration of 1ug/ml. This photo is the merge of PE and DAPI. (40X)
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human placenta using 60067-1-Ig(NRP1 antibody) at dilution of 1:50 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human placenta using 60067-1-Ig(NRP1 antibody) at dilution of 1:50 (under 40x lens)
- Sample type
- tissue
